Stock comparison
ResMed
Zoetis
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$29.57B
Sector
Healthcare
ZTS
Zoetis
Market cap
$31.17B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | ZTS | Winner |
|---|---|---|---|
| Warren Buffett | 64C | 57C | RMD |
| Benjamin Graham | 67B | 62C | RMD |
| Philip Fisher | 67B | 53C | RMD |
| Peter Lynch | 50C | 34F | RMD |
| Joel Greenblatt | 39D | 35D | RMD |
| Charlie Munger | 61C | 61C | Tie |
| Terry Smith | 65B | 65B | Tie |
Side-by-side metrics
| Metric | RMD | ZTS |
|---|---|---|
| Market cap | $29.57B | $31.17B |
| P/E (TTM) | 19.6x | 11.9x |
| EV/EBIT | 17.1x | 10.8x |
| ROIC (TTM) | 19.63% | 21.79% |
| Gross margin | 61.69% | 70.75% |
| Net margin | 27.44% | 27.79% |
| Revenue CAGR 5y | 12.64% | 5.04% |
| EPS CAGR 5y | 30.73% | 8.88% |
| Debt / Equity | 0.1x | 0.1x |
| Dividend yield | 1.14% | 2.77% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- EPS CAGR 5y30.73%vs 8.88%+71%
- Revenue CAGR 5y12.64%vs 5.04%+60%
ZTS leads on
- Dividend yield2.77%vs 1.14%+59%
- Debt / Equity0.1xvs 0.1x+54%
- P/E (TTM)11.9xvs 19.6x+40%
- EV/EBIT10.8xvs 17.1x+37%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.